These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22641062)

  • 21. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method.
    Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD
    Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroral amphotericin B polymer nanoparticles lead to comparable or superior in vivo antifungal activity to that of intravenous Ambisome® or Fungizone™.
    Italia JL; Sharp A; Carter KC; Warn P; Kumar MN
    PLoS One; 2011; 6(10):e25744. PubMed ID: 21998690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
    Kaur K; Kumar P; Kush P
    Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes.
    Clemons KV; Ranney DF; Stevens DA
    Curr Opin Investig Drugs; 2001 Apr; 2(4):480-7. PubMed ID: 11566003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of liposomal amphotericin B with prolonged circulation in blood versus those of AmBisome and fungizone against intracellular Candida albicans in murine peritoneal macrophages.
    van Etten EW; van Vianen W; Hak J; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2437-9. PubMed ID: 9736579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
    Gangadhar KN; Adhikari K; Srichana T
    Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
    Warn PA; Sharp A; Morrissey G; Denning DW
    Int J Antimicrob Agents; 2010 Feb; 35(2):146-51. PubMed ID: 20015618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
    Graybill JR; Kaster SR
    Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.
    Costa Lima SA; Resende M; Silvestre R; Tavares J; Ouaissi A; Lin PK; Cordeiro-da-Silva A
    Nanomedicine (Lond); 2012 Dec; 7(12):1839-49. PubMed ID: 22812711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans.
    Chudzik B; Tracz IB; Czernel G; Fiołka MJ; Borsuk G; Gagoś M
    Eur J Pharm Sci; 2013 Aug; 49(5):850-7. PubMed ID: 23791641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells.
    Legrand P; Chéron M; Leroy L; Bolard J
    J Drug Target; 1997; 4(5):311-9. PubMed ID: 9169988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amphotericin B-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carrier (NLCs): effect of drug loading and biopharmaceutical characterizations.
    Jansook P; Pichayakorn W; Ritthidej GC
    Drug Dev Ind Pharm; 2018 Oct; 44(10):1693-1700. PubMed ID: 29936874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B.
    Pandya S; Verma RK; Khare P; Tiwari B; Srinivasarao DA; Dube A; Goyal N; Misra A
    Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):125-32. PubMed ID: 27183429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro inhibition of fungal activity by macrophage-mediated sequestration and release of encapsulated amphotericin B nanosupension in red blood cells.
    Staedtke V; Brähler M; Müller A; Georgieva R; Bauer S; Sternberg N; Voigt A; Lemke A; Keck C; Möschwitzer J; Bäumler H
    Small; 2010 Jan; 6(1):96-103. PubMed ID: 19882684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
    Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system.
    Khan AA; Alanazi AM; Jabeen M; Khan S; Malik A
    Eur J Pharm Sci; 2018 Jul; 119():171-178. PubMed ID: 29653177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.
    Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2004 Mar; 48(3):1047-50. PubMed ID: 14982807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
    Bellocchio S; Gaziano R; Bozza S; Rossi G; Montagnoli C; Perruccio K; Calvitti M; Pitzurra L; Romani L
    J Antimicrob Chemother; 2005 Feb; 55(2):214-22. PubMed ID: 15649994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.